keyword
MENU ▼
Read by QxMD icon Read
search

decapeptyl 0.1

keyword
https://www.readbyqxmd.com/read/27462292/cognitive-emotional-and-psychosocial-functioning-of-girls-treated-with-pharmacological-puberty-blockage-for-idiopathic-central-precocious-puberty
#1
Slawomir Wojniusz, Nina Callens, Stefan Sütterlin, Stein Andersson, Jean De Schepper, Inge Gies, Jesse Vanbesien, Kathleen De Waele, Sara Van Aken, Margarita Craen, Claus Vögele, Martine Cools, Ira R Haraldsen
Central precocious puberty (CPP) develops due to premature activation of the hypothalamic-pituitary-gonadal (HPG) axis, resulting in early pubertal changes and rapid bone maturation. CPP is associated with lower adult height and increased risk for development of psychological problems. Standard treatment of CPP is based on postponement of pubertal development by blockade of the HPG axis with gonadotropin releasing hormone analogs (GnRHa) leading to abolition of gonadal sex hormones synthesis. Whereas the hormonal and auxological effects of GnRHa are well-researched, there is a lack of knowledge whether GnRHa treatment influences psychological functioning of treated children, despite the fact that prevention of psychological problems is used as one of the main reasons for treatment initiation...
2016: Frontiers in Psychology
https://www.readbyqxmd.com/read/27356090/luteinising-hormone-releasing-hormone-lhrh-agonists-for-the-treatment-of-relapsed-epithelial-ovarian-cancer
#2
REVIEW
Rekha Wuntakal, Srividya Seshadri, Ana Montes, Geoff Lane
BACKGROUND: Ovarian cancer is seventh most common cancer in women worldwide. Approximately 1.3% of women will be diagnosed with ovarian cancer at some point during their life time. The majority of tumours arise from surface of the ovary (epithelial). Two thirds of these women will present with advanced disease, requiring aggressive treatment, which includes debulking surgery (removal of as much disease as possible) and chemotherapy. However, most women (75%) with advanced epithelial ovarian cancer (EOC) will relapse following surgery and chemotherapy...
2016: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/26935495/the-influence-of-gnrh-analog-therapy-on-growth-in-central-precocious-puberty
#3
Ewa Głąb, Beata Wikiera, Jolanta Bieniasz, Ewa Barg
BACKGROUND: Children with central precocious puberty (CPP) present various somatic and psychological abnormalities. OBJECTIVES: The aim of the study was to evaluate growth changes in girls with central precocious puberty treated with GnRH analog therapy and to analyze the factors affecting the auxological response to this treatment. MATERIAL AND METHODS: The study group consisted of 40 girls with puberty onset aged 6.0 ± 1.9 years (mean, ± SD), treated with 3...
January 2016: Advances in Clinical and Experimental Medicine: Official Organ Wroclaw Medical University
https://www.readbyqxmd.com/read/26455014/-changes-in-blood-pressure-and-heart-rate-by-an-increase-in-serum-estradiol-in-women-undergoing-controlled-ovarian-hyperstimulation
#4
Rita Tomczy, Katarzyna Paluch, Anna Gałuszka-Bednarczyk, Tomasz Milewicz, Jarosław Janeczko, Marek Klocek
UNLABELLED: The aim of the study was to evaluate changes in blood pressure and heart rate in women undergoing controlled ovarian stimulation (COH) in preparation for assisted reproduction techniques. Material and method: The comparison of blood pressure and heart rate measurements obtained from 5 women (age 35.3 +/- 9.4 years) was performed. The data were collected during the 24-hour ambulatory blood pressure monitoring (ABPM) using Holcard sphygmomanometer CR-07 Aspel S.A. at the beginning and in the last day of short protocol of COH with the use of triptorelin (Decapeptyl 0...
2015: Przegla̧d Lekarski
https://www.readbyqxmd.com/read/25160805/luteal-phase-support-with-decapeptyl-improves-pregnancy-outcomes-in-intracytoplasmic-sperm-injection-with-higher-basal-follicle-stimulating-hormone-or-lower-mature-oocytes
#5
Hsiao-Fan Kung, Ming-Jer Chen, Hwa-Fen Guua, Ya-Fang Chen, Yu-Chiao Yi, Jason Yen-Ping Ho, Min-Min Chou
BACKGROUND: The role of midluteal phase gonadotropin-releasing hormone (GnRH) agonist had been an issue of debate. The aim of this retrospective study was to evaluate the effect of a mid-luteal phase GnRH agonist as an additional luteal phase support (LPS) in patients receiving intracytoplasmic sperm injection (ICSI). Additionally, we elucidate which subgroup would gain the most benefit from GnRH agonist as LPS. METHODS: The medical records were retrieved from January 2009 to January 2012 and a total of 348 patients receiving ICSI were included in this retrospective study...
October 2014: Journal of the Chinese Medical Association: JCMA
https://www.readbyqxmd.com/read/24639738/comparison-of-pregnancy-outcome-in-half-dose-triptorelin-and-short-acting-decapeptyl-in-long-protocol-in-art-cycles-a-randomized-clinical-trial
#6
Maryam Eftekhar, Elham Rahmani, Farnaz Mohammadian
BACKGROUND: Gonadotrophin-releasing hormone (GnRH) agonist is used for controlling ovarian stimulation in assisted reproductive technology (ART) cycles which has some benefits. OBJECTIVE: To compare the efficacy of two different formulations of GnRH agonist: short-acting and long-acting, for ART protocols. MATERIALS AND METHODS: In a prospective randomized study, one hundred women who underwent ART cycles were randomly divided into two groups...
February 2013: Iranian Journal of Reproductive Medicine
https://www.readbyqxmd.com/read/20022282/-efficiency-of-antagonist-ivf-cycle-programming-by-estrogens
#7
RANDOMIZED CONTROLLED TRIAL
A Guivarc'h-Levêque, P Arvis, J-L Bouchet, P-L Broux, L Moy, G Priou, J Vialard, D Colleu
OBJECTIVE: Assess the efficiency of estradiol programming in In Vitro Fertilization (IVF) with antagonists by comparing with classical long luteal agonist protocol. PATIENTS AND METHODS: It is a prospective randomized study, comparing 426 cycles in the arm estradiol antagonist with 412 cycles in the arm long agonist. Estradiol 4 mg/day begins on the 25th day of the previous cycle and continues during the menses until the first day of the stimulation which is from Thursday to Sunday whatever the beginning of the menses...
January 2010: Gynécologie, Obstétrique & Fertilité
https://www.readbyqxmd.com/read/19454183/influence-of-gnrh-analog-therapy-on-body-mass-in-central-precocious-puberty
#8
Ewa Głab, Ewa Barg, Beata Wikiera, Marcin Grabowski, Anna Noczyńska
THE AIM OF THE STUDY: Was to evaluate the body mass index (BMI) changes in girls with central precocious puberty (CPP) treated with a GnRH analog (GnRHa) and to analyse the factors affecting BMI. MATERIAL AND METHODS: 43 girls with puberty onset aged (mean, +/-SD) 6.1+/-1.9, treated with 3.75 mg Decapeptyl Depot i.m. every 28 days. The treatment was initiated at the age of 7.5+/-2.1 year and continued for 3.3+/-2.2 year until the age of 11.4+/-0.9 year. The height, weight and BMI data were evaluated before, during and after GnRH agonist administration...
2009: Pediatric Endocrinology, Diabetes, and Metabolism
https://www.readbyqxmd.com/read/17219967/efficacy-of-subcutaneous-administration-of-gonadotropin-releasing-hormone-agonist-on-idiopathic-central-precocious-puberty
#9
Yan Liang, Hong Wei, Jianling Zhang, Ling Hou, Xiaoping Luo
In order to assess the feasibility of subcutaneous administration of Triptorelin with 6-week intervals for the suppression of pituitary-gonadal axis and changes of clinical signs in girls with idiopathic central precocious puberty (ICPP), 46 girls with ICPP were treated with GnRHa. Triptorelin (Decapeptyl, 3.75 mg) was administered subcutaneously (SC) at 6-weeks intervals or intramuscularly (IM) at 4-weeks intervals randomly for more than 12 months consecutively. During GnRHa therapy, clinical parameters and laboratory data, including height, weight, pubertal stage, bone age, uterine volume and ovarian size, serum levels of luteinizing hormone (LH), follicle stimulating hormone (FSH) and estradiol (E2), were monitored and analyzed...
2006: Journal of Huazhong University of Science and Technology. Medical Sciences
https://www.readbyqxmd.com/read/16679296/combined-use-of-growth-hormone-and-gonadotropin-releasing-hormone-analogue-in-short-normal-adolescent-girls-a-survey-from-iran
#10
Zohreh Karamizadeh, Mohammad Amin Kashef, Hamed Jalaeian, Najmeh Namazee
Combined therapy with gonadotropin-releasing hormone (GnRH) analogue and growth hormone (GH) has been used to increase the height of adolescents who are not GH deficient and who have normally timed puberty. Its use, however, is still controversial. For 2 years simultaneously, we treated eight healthy girls with very low predicted adult height (PAH < 145 cm) who were entering into normally timed puberty. The GnRH analogue triptorelin pamoate (Decapeptyl, 100 microg/kg intramuscularly every 4 weeks) and GH (0...
April 2006: Kaohsiung Journal of Medical Sciences
https://www.readbyqxmd.com/read/16026401/short-term-and-long-term-results-of-resectoscopic-myomectomy-with-and-without-pretreatment-with-gnrh-analogs-in-premenopausal-women
#11
COMPARATIVE STUDY
Sebastiano Campo, Vincenzo Campo, Pietro Gambadauro
OBJECTIVE: The aim of this study was to analyze the safety and efficacy of resectoscopic myomectomy and to evaluate the influence of GnRH analog pretreatment on short- and long-term surgery outcome. METHODS: Data were collected from 80 consecutive resectoscopic myomectomies performed on premenopausal women. Forty-two patients (52.5%) had not received any preoperative medical treatment and in their case surgery was performed during the early proliferative phase (group A), whereas 38 patients (47...
August 2005: Acta Obstetricia et Gynecologica Scandinavica
https://www.readbyqxmd.com/read/15990256/endocrine-morphological-and-cytological-effects-of-a-depot-gnrh-agonist-in-bovine
#12
COMPARATIVE STUDY
F Schneider, B Heleil, H Alm, H Torner, F Becker, T Viergutz, G Nürnberg, W Kanitz
The present study was conducted to assess effects of the gonadotropin-releasing hormone agonist (GnRHa) triptorelin in dairy heifers. The peptide was released from a commercial 4-week depot formulation (Decapeptyl Depot) administered at animals' estrus (day 0). First experiment (EXP I, n=5), which was aimed to explore the availability of peptide, detected a maximum of triptorelin concentration between day 2 and 5 after depot injection, and the peptide remained detectable by RIA in peripheral blood for about 3 weeks...
March 2006: Animal Reproduction Science
https://www.readbyqxmd.com/read/15702449/-body-mass-index-protein-metabolism-profiles-and-impact-on-ivf-icsi-procedure-and-outcome
#13
W Munz, C Fischer-Hammadeh, W Herrmann, T Georg, P Rosenbaum, W Schmidt, M E Hammadeh
OBJECTIVE: Higher risks of infertility have been found in overweight women. The purpose of the present study was to explore whether protein metabolism profiles related to body mass index (BMI) and to find out whether these parameters should affect IVF/ICSI outcome. PATIENTS AND METHODS: 52 patients were enrolled in this study. All patients underwent an ovarian stimulation either with recombinant follicle stimulating hormone (Gonal-F) or human menopausal gonadotropin (Menogon) after pituitary down-regulation with Goserelin (Zoladex) or Triptorelin (Decapeptyl Gyn)...
February 2005: Zentralblatt Für Gynäkologie
https://www.readbyqxmd.com/read/15631714/-clinical-study-of-subcutaneous-administration-of-gonadotropin-releasing-hormone-agonist-every-six-weeks-in-girls-with-idiopathic-central-precocious-puberty
#14
RANDOMIZED CONTROLLED TRIAL
Yan Liang, Hong Wei, Jian-ling Zhang, Ling Hou, Xiao-ping Luo
OBJECTIVE: Gonadotropin-releasing hormone agonist (GnRHa) is widely used for the treatment of precocious puberty, but there was no identical regime for the dosage and the interval of administration. The aim of this study was to assess the feasibility of subcutaneous administration of Triptorelin with a prolonged interval (six weeks) for the suppression of pituitary-gonadal axis and clinical signs in girls with idiopathic central precocious puberty (ICPP). METHODS: Forty-six girls with ICPP were enrolled in this trial and were divided into two groups at random, with 26 patients in group A and 20 in group B...
November 2004: Zhonghua Er Ke za Zhi. Chinese Journal of Pediatrics
https://www.readbyqxmd.com/read/15499224/pharmacodynamic-equivalence-of-a-decapeptyl-3-month-sr-formulation-with-the-28-day-sr-formulation-in-patients-with-advanced-prostate-cancer
#15
RANDOMIZED CONTROLLED TRIAL
Pierre Teillac, Christiaan F Heyns, Amir V Kaisary, Olivier Bouchot, Joëlle Blumberg
AIMS: The objective of the study was to assess the pharmacodynamic equivalence of LHRH analogue triptorelin 3-month and 28-day SR formulations. METHODS: Patients with documented locally advanced or metastatic prostate cancer were randomized to receive one injection of the 3-month formulation (n = 63) or three injections at 28-day intervals of the 28-day formulation (n = 68). Group-chemical castration rates defined as the percentage of patients reaching a testosterone plasma level </=0...
2004: Hormone Research
https://www.readbyqxmd.com/read/15195497/relationship-between-gonadotropin-releasing-hormone-agonist-dosage-and-in-vitro-fertilization-outcome
#16
F Lorusso, R Depalo, L Selvaggi
A prospective study in 132 women undergoing in vitro fertilization was performed in order to assess whether lower doses of gonadotropin releasing hormone agonists (GnRH-a) may ensure adequate oocyte retrieval and pregnancy rate, without pituitary oversuppression. Forty-five patients received subcutaneous tryptorelin depot (Decapeptyl 3.75, IPSEN SpA), 41 received subcutaneous tryptorelin acetate daily (Decapeptyl 0.1 mg, IPSEN SpA) and 46 received 0.05 mg tryptorelin acetate daily from day 21 of the cycle. From day 3 of the new cycle, if the estradiol levels were < 30 pg/ml, patients received two or three ampules of gonadotropin daily...
February 2004: Gynecological Endocrinology
https://www.readbyqxmd.com/read/14746863/antagonists-of-growth-hormone-releasing-hormone-gh-rh-enhance-tumour-growth-inhibition-induced-by-androgen-deprivation-in-human-mda-pca-2b-prostate-cancers
#17
M Letsch, A V Schally, A Stangelberger, K Groot, J L Varga
In the present study, we investigated whether the growth hormone-releasing hormone (GH-RH) antagonist JV-1-38 could enhance the effects of androgen deprivation produced by the anti-androgen Flutamide and luteinising hormone-releasing hormone (LH-RH) agonist Decapeptyl in an experimental model of human androgen-sensitive MDA PCa 2b prostate carcinoma implanted subcutaneously (s.c.) into nude mice. We also evaluated by reverse transcriptase-polymerase chain reaction (RT-PCR) the effects of combined treatment on the mRNA expression for prostate-specific antigen (PSA) and measured serum PSA levels...
February 2004: European Journal of Cancer
https://www.readbyqxmd.com/read/12834940/doppler-ultrasound-as-a-predictor-of-uterine-fibroid-response-to-gnrh-therapy
#18
N Kanelopoulos, S Dendrinos, A Oikonomou, P Panagopoulos, V Markussis
OBJECTIVES: GnRH agonists (GnRHa) are able to reduce the bleeding and size of fibroids. We monitored the response of fibroids to GnRHa with power-Doppler ultrasound. METHODS: Thirty-five women with fibroids, aged 32-48, received a 6-month course with the GnRHa triptorelin (Decapeptyl, Ipsen, France). The resistance index (RI) of the uterine artery was measured with power-Doppler ultrasound. RESULTS: The uterine volume reduced from 470+/-347 to 297+/-295 cm3 (P<0...
July 2003: International Journal of Gynaecology and Obstetrics
https://www.readbyqxmd.com/read/12030910/use-of-gnrh-agonist-and-human-chorionic-gonadotrophin-tests-for-differentiating-constitutional-delayed-puberty-from-gonadotrophin-deficiency-in-boys
#19
Arieh Kauschansky, Zvi Dickerman, Moshe Phillip, Naomi Weintrob, David Strich
OBJECTIVES: The differentiation of constitutional delayed puberty (CDP) from gonadotrophin deficiency (GD) in boys at referral poses a difficult challenge. The effectiveness of the GnRH agonist (GnRH-a) test in distinguishing between the two conditions was evaluated and compared with findings of the GnRH and hCG stimulation tests. PATIENTS, METHODS AND DESIGN: The study sample included 32 prepubertal boys aged 14 years or older. Thirteen entered spontaneous puberty within 1 year of referral (group A) and 19 remained prepubertal (group B)...
May 2002: Clinical Endocrinology
https://www.readbyqxmd.com/read/11730823/effects-of-androgen-manipulation-on-postprandial-triglyceridaemia-low-density-lipoprotein-particle-size-and-lipoprotein-a-in-men
#20
COMPARATIVE STUDY
M S Hislop, A St Clair Gibson, M I Lambert, T D Noakes, A D Marais
Although androgenic hormones decrease HDLC concentration, no direct evidence has linked them to atherosclerosis. The present study was undertaken to extend our ability to assess risk associated with androgen induced lipoprotein(Lp) changes by simultaneously gathering information about postprandial triglyceridaemia (PPT), LDL particle size, HDL and Lp(a) in men either taking exogenous androgens or with suppressed endogenous androgen concentrations. The experimental groups comprised nine male bodybuilders who self-administered anabolic-androgenic steroids (AAS) for a mean period of 6...
December 2001: Atherosclerosis
keyword
keyword
102187
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"